Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia

Bibliography

• Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase no 10. International Agency for Research on Cancer, Lyon, France; 2010. Available from: http://globocan.iarc.fr
   Google Scholar
• Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65
   PubMed Web of Science ®Google Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32:S16-24
   PubMed Web of Science ®Google Scholar
• Plummer M, Schiffman M, Castle PE, for the ALTS group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-9
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Schiffman M, Dunn ST, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1700 women referred to colposcopy in Oklahoma. Int J Cancer 2009;124:964-9
   PubMed Web of Science ®Google Scholar
• Darragh TM, Colgan TJ, Cox T, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations for the College of American Pathologists and the American Society of Colposcopy and Cervical Pathology 2012. Arch Pathol Lab Med 2012;136:1266-97
   PubMed Web of Science ®Google Scholar
• Wells M, Ostor AG, Crum CP. Epithelial tumours. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. 1st edition. IARC; Lyon, France: 2003. p. 259-90
   Google Scholar
• Östör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92
   PubMed Web of Science ®Google Scholar
• McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34
   PubMed Web of Science ®Google Scholar
• Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. ObstetGynecol 2013;121:829-46
   Web of Science ®Google Scholar
• Spitzer M, Chelmow D. Practice Bulletin - management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol 2013;122:1338-67
   PubMedGoogle Scholar
• Ferenczy A. Management of patients with high grade squamous intraepithelial lesions. Cancer 1995;76:1928-33
   PubMed Web of Science ®Google Scholar
• Wright TCJ, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197(4):340-5
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy and cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006;32:516-23
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-98
   PubMed Web of Science ®Google Scholar
• Noehr B, Jensen A, Frederiksen K, et al. Loop electrosurgical excision of the cervix and subsequent risk of spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J ObstetGynecol 2009;201:33.e1-6
   PubMed Web of Science ®Google Scholar
• Albrechtsen S, Rasmussen S, Thoresen S, et al. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ 2008;18:337
   Google Scholar
• Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284
   PubMed Web of Science ®Google Scholar
• Simoens C, Goffin F, Barlow P, et al. Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgium multicenter study. BJOG 2012;119:1247-55
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. World Health Organization, Geneva; 2013. Available from: http://www.ncbi.nlm.nih.gov/books/NBK195239/
   Google Scholar
• Garcia-Hernandez E, Gonzalez- Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006;3:592-7
   Google Scholar
• Garcia F, Petry KU, Muderspach L, et al. ZYC 101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317-26
   PubMed Web of Science ®Google Scholar
• Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007;106:453-60
   PubMed Web of Science ®Google Scholar
• Grimm C, Polterauer S, Natter C, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod. Obstet Gynecol 2012;120:152-9
   PubMed Web of Science ®Google Scholar
• van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465-73
   PubMed Web of Science ®Google Scholar
• Pachman DR, Barton DC, Clayton A, et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am J Obstet Gynecol 2012;206:e1-7
   PubMedGoogle Scholar
• Grabosch SM, Shariff OM, Wulff JL, Helm CW. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2014;4:CD004121
   PubMedGoogle Scholar
• Bell MC, Crowley-Nowick P, Bradlow H, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9
   PubMed Web of Science ®Google Scholar
• van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 2009;115:69-74
   PubMed Web of Science ®Google Scholar
• Kietpeerakool C, Srisomboon J. Medical treatment of cervical intraepithelial neoplasia II, III: an update review. Int J Clin Oncol 2009;14:37-42
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46
   PubMed Web of Science ®Google Scholar
• Hillemanns P, Wang X, Hertel H, et al. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2008;198:300.e1-7
   PubMedGoogle Scholar
• Andrejevic-Blant S, Major A, Lüdicke F, et al. Time-dependent hexaminolevulinate-induced protoporphyrin IX distribution after topical application in patients with cervical intraepithelial neoplasia: a fluorescence microscopy study. Lasers Surg Med 2004;35:276-83
   PubMed Web of Science ®Google Scholar
• PC CO102/09 Clinical Study Report. An open label, single dose, three period study to determine the pharmacokinetic parameters of hexaminolevulinate (HAL) hydrochloride after intravenous, vaginal and enema administration to healthy female volunteers. 23 June 2011
   Google Scholar
• Soergel P, Wang X, Stepp H, et al. Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers Surg Med 2008;40:611-15
   PubMed Web of Science ®Google Scholar
• Soergel P, Dahl GF, Onsrud M, Hillemanns P. Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate - a double-blind, dose-finding study. Lasers Surg Med 2012;44:468-74
   PubMed Web of Science ®Google Scholar
• Soergel P, Loehr-Schulz R, Hillemanns M, et al. Effects of photodynamic therapy using topical applied hexylaminolevulinate and methylaminolevulinate upon the integrity of cervical epithelium. Lasers Surg Med 2010;42:624-30
   PubMed Web of Science ®Google Scholar
• Hillemanns P, Petry KU, Soergel P, et al. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia. Lasers Surg Med 2014;10.1002/lsm.22255. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Einstein M, Sordal T, Lunde T. Safety of hexaminolevulinate photodynamic therapy - a non-extirpative treatment for cervical neoplasia (CIN). ASCCP; San Francisco: 2012
   Google Scholar
• Hillemanns P, Garcia F, Petry K U, et al. A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Accepted for publication American Journal of Obstetrics & Gynecology, 2014, currently available online ahead of publication
   Google Scholar